TrialJournal for immunotherapy of cancer2021

Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival.

Manish A Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.